Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Oct 1 - Oct 6
This post reviews the proposed foundations behind integrating GLP-1 agonists into psychiatric care for patients with comorbid obesity
The potential benefits of such treatment (long-term weight reduction, prevention of diabetes and diabetic complications, including cardiovascular events) need to be demonstrated in large clinical trials, but this earlier-stage population may provide unique chances to reveal benefits that cannot be shown at later stages, when the degree of tissue damage has advanced to an irreversible state
Supply of weight loss injections has fluctuated in recent years, and switching is sometimes the only way to avoid a gap in treatment
So, exogenous GLP-1R agonists have been more recently considered as a good choice for treating patients with diabetes [29]
US$ 26.28
US$ 21.23
US$ 29.74
US$ 25.79
US$ 28.39
